2021
DOI: 10.4067/s0719-81322021000100047
|View full text |Cite
|
Sign up to set email alerts
|

Animal models of chronic pain. Are naturally occurring diseases a potential model for translational research?

Abstract: Despite the vast amount of molecular data obtained from classical pain studies, there is an ongoing translational pain model crisis reflected by the reduced amount of new effective and safe compounds developed to treat chronic pain in humans. Naturally occurring chronic pain in animals may offer some advantages over induced models of chronic pain, including a natural development of the condition that induces pain, the heterogenicity of the population that affects, and the chronologic age in which they develop,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
14
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 10 publications
(14 citation statements)
references
References 86 publications
0
14
0
Order By: Relevance
“…The translation gap between preclinical and clinical efficacy has called into question the reliability of animal models of human pain conditions. A review by Herzberg and Bustamante (2021) reported failure rates of 90–95% in the clinical phase of drug development, and in 2010, it was revealed that the likelihood of an analgesic drug progressing beyond Phase I clinical trials was 10.7% ( Hay et al, 2014 ; as cited in Herzberg and Bustamante, 2021 ). The poor translation from animal studies to humans in the clinic may be a culmination of limitations such as behavioral testing favoring the sensory over the emotional aspects of pain and insufficient diversity among study cohorts.…”
Section: Pain Modelsmentioning
confidence: 99%
See 3 more Smart Citations
“…The translation gap between preclinical and clinical efficacy has called into question the reliability of animal models of human pain conditions. A review by Herzberg and Bustamante (2021) reported failure rates of 90–95% in the clinical phase of drug development, and in 2010, it was revealed that the likelihood of an analgesic drug progressing beyond Phase I clinical trials was 10.7% ( Hay et al, 2014 ; as cited in Herzberg and Bustamante, 2021 ). The poor translation from animal studies to humans in the clinic may be a culmination of limitations such as behavioral testing favoring the sensory over the emotional aspects of pain and insufficient diversity among study cohorts.…”
Section: Pain Modelsmentioning
confidence: 99%
“…However, there are concerns regarding the ability of these models to reflect the emotional facets of pain ( King et al, 2009 ; Herzberg and Bustamante, 2021 ). To attain a more complete perspective of pain in animal studies, it has been suggested to analyze evoked pain outcomes, via mechanical or thermal stimulation, alongside non-evoked tests which better assess the quality of life ( Mogil, 2009 ; Burma et al, 2017 ; Herzberg and Bustamante, 2021 ). For example, conditioned place preference experiments can determine if an analgesic drug is perceived as rewarding, indicating an overall improvement in the experience of the rodent ( King et al, 2009 ).…”
Section: Pain Modelsmentioning
confidence: 99%
See 2 more Smart Citations
“…As well as impacting on humans, chronic pain also occurs naturally in livestock e.g. sheep, cattle and swine [ 115 ] and therefore could be a candidate for a One Medicine approach, whilst corneal ulcers in sea lions have seen novel treatments developed based on applications from human medicine [ 116 ].…”
Section: One Medicine In Other Areasmentioning
confidence: 99%